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Abstract  
BACKGROUND: Congenital melanocytic nevi (CMN) are pigmented skin lesions usually present at birth. Rare 
varieties can develop and become clinically very large. Although they are benign nevomelanocytic neoplasms, all 
CMN may be precursors of the melanoma, regardless of their size. Individual risk of malignant transformation of 
melanocyte is determined by simultaneous action of exogenous and endogenous factors. The major exogenous 
risk factor is ultraviolet radiation. Leading roles among the endogenous factors are attributed to skin phenotype, 
gene mutation, sex hormones and their significance. 
CASE REPORT: We present a case of a 27 – year - old pregnant female patient with a congenital melanocytic 
nevus, which increased significantly in size, during her pregnancy. Estrogen levels increase during pregnancy and 
clinical evidence has suggested that melanocytes are estrogen - responsive. Nevi in a pregnant patient would 
exhibit increased expression of estrogen receptor β (ERβ) and thus enhanced the potential to respond to altered 
estrogen levels. 
CONCLUSION: All pigmented skin lesions should be carefully observed during pregnancy by a dermatologist due 
to the increased risk of malignant transformation, associated with the endocrine dependence. All lesions with 
visible changes should be removed surgically with appropriative anaesthesia. 
 
 
 
 
 
 
 
 
Introduction 
 
Despite aesthetic, congenital melanocytic nevi 
can cause health problems. Usually they are classified 
by size: small (< 1.5 cm in diameter), medium (1.5 – 
19.9 cm) and large or giant (≥ 20) [1]. Independently 
of their size, all congenital melanocytic nevi are 
associated with increased risk of development of 
melanoma [1]. The risk of malignant transformation is 
higher in giant congenital nevi, and they should be 
carefully monitored biopsied if indicated [2]. 
The most prominent and predictable 
progression could be seen in the middle sized 
melanocytic nevi by dermoscopic and clinical 
evaluation, because: 
1. The giant congenital melanocytic nevi often 
show areas which are clinically and dermoscopically 
difficult to differentiate from melanoma [3]. In these 
cases (patients with giant congenital melanocytic nevi) 
surgical excision is rarely due to the enlarged size of 
the lesions [4][5]. Confocal laser dermoscopy and 
PET CT can be useful to diagnose melanoma [6]. 
2. Small congenital melanocytic nevi or so-
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called congenital pseudomelanomas are often 
clinically and dermoscopically indistinguishable from 
real melanomas. Histopathological verification of the 
above-mentioned lesions are also subjected to lively 
discussions; therefore differentiation of melanoma is 
extremely difficult. 
These two facts are giving a new perspective 
on diagnosis and choosing of the most appropriate 
treatment option for the medium-sized melanocytic 
nevi, namely by surgery [3][4][5]. Progression of 
normal and dysplastic nevi to melanoma during 
pregnancy is an interesting topic which at the moment 
does not find a definitive solution [7]. 
 
 
Case report 
 
We present a case of a 27 – year - old female 
patient, with a pigmented lesion measuring 3 x 5 cm, 
located above the right gluteal area since early 
childhood. The lesion was asymptomatic and had not 
shown any changes in size or colour for the last 20 
years. There was no evidence of significant 
comorbidities or medical treatment. During pregnancy, 
the patient noticed peripheral enlargement of the 
lesion as well as the intensification of the dark hue. 
The latest changes prompted the patient to seek 
medical consultation at the dermatological clinic. A 
large melanocytic nevus was established within the 
clinical examination, located above the right gluteal 
area with asymmetric shape, uneven boundaries at 
the periphery, no uniform colour in the different areas 
of the lesion as well as the difference in diameter – 
east, west, north, south, but no elevation of the lesion. 
 
Figure 1: a, b) Clinical view of the lesion located above the right 
gluteal area; c, d) Consecutive stages within the excision of the 
lesion 
The diagnosis of medium-sized congenital 
melanocytic nevus was confirmed by the medical 
history, dermoscopic and clinical signs of dysplasia 
and progression during pregnancy. The lesion was 
surgically removed under local anaesthesia (Fig.1 a, 
b, c, d). The histopathological evaluation concluded 
the diagnosis of medium-sized congenital pigmented 
congenital melanocytic nevus with minimal cytological 
atypia and clear surgical margins. 
Since pregnancy is a sure risk factor for the 
progression of normal nevi to dysplastic or dysplastic 
nevi to melanoma, we recommend surgical treatment 
as a preferable option. 
 
 
Discussion 
 
It is well known that the frequency and 
prognosis of melanoma in women are influenced by 
hormonal and reproductive factors [7]. It is also well 
established that the prognosis and survival rate in 
premenopausal women is better than postmenopausal 
[8]. In the last years there has been increased 
interested and discussion about the impact of 
pregnancy on nevi and their malignant transformation 
[7][9][10]. New theories and approaches have been 
advanced to explain the interplay between hormones 
and pathological changes in nevi [11]. One of the 
hypotheses is the influence of estrogen expression. 
Beneficial and protective effects on the skin have 
estrogen receptors: estrogen – receptor α (ERα) and 
estrogen - receptor β (ERβ) [12]. Significant 
differences in the concentrations of these receptors 
have been established in sections of melanocytic 
lesions and those with healthy skin as well as in 
pregnant and non- pregnant women’s skin  [13]. 
Subtype β is a predominant receptor in melanocytes 
and its protective function is well known  [12]. ERβ is 
antagonist against uncontrolled cell- proliferation and 
tumor growth [12][14]. An increased in the 
immunoreactivity for ERβ was observed in normal 
nevi during pregnancy [15]. The immunoreactivity for 
ERβ was found to decreases with such deeply 
extending cells [16][17]. Loss of ERβ expression and 
its presumed inhibitory effects may promote 
transformation into melanoma, which is a key event in 
neoplastic progression [18]. Several studies show 
reduced expression of ERβ in metastatic stages of 
malignant melanoma [19], in the presence of a greater 
thickness of the dysplastic nevi [20]. The clinical 
implications of such altered ERβ expressions remains 
underestimated. Different hypothesis explains the 
higher risk of malignancy during pregnancy with the 
increased levels of male sex hormones- androgens 
[21]. There is a theory that endocrine effect reduces 
after first pregnancy. During second and third 
pregnancy the risk of development of malignant 
melanoma (MM) is lower due to the presence of 
antibodies against tumor-associated fetal antigens. 
Thus, during first pregnancy the risk of malignant 
transformation is increased, while every subsequent 
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pregnancy has a protective effect [22]. Recently, 
mutations in two tumor suppressive gens - BAP1 
(BRCA - associated protein 1) and BRAF (V - raf 
murine sarcoma virus oncogene homolog B1) have 
been associated with increased susceptibility for 
development of MM and other atypical epithelial 
lesions [23][24]. Screening for mutation/loss/ 
inactivation of BAP1 and BRAFV600E can be 
performed by immunohistochemistry. Most 
melanocytic lesions show positive BAP1 nuclear 
staining. BRAFV600E is positive in 5% of congenital 
melanocytic nevus [23][25] 
The potential relationship between dysplastic 
nevi and malignant transformation during pregnancy is 
underestimated [26][27]. However, all pigment skin 
lesions should be carefully observed during this period 
[26][27]. In our case of a 27 – years - old pregnant 
woman, with CMN, which significantly increased its 
size and changed its colour and therefore, we decide 
to remove the lesions surgically, because of the 
increased risk of malignant transformation. 
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